RHYTHM Biosciences Ltd (RHY) - Cash Flow Conversion Efficiency
Based on the latest financial reports, RHYTHM Biosciences Ltd (RHY) has a cash flow conversion efficiency ratio of -1.037x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-2.22 Million ≈ $-1.57 Million USD) by net assets (AU$2.14 Million ≈ $1.52 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See RHY defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
RHYTHM Biosciences Ltd - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how RHYTHM Biosciences Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
RHYTHM Biosciences Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of RHYTHM Biosciences Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
DL Holdings Co Ltd Preferred
KO:000215
|
0.073x |
|
Dataproces Group A/S
CO:DATA
|
-0.033x |
|
Sanatana Resources
V:STA
|
-0.300x |
|
Blue Star Helium Ltd
AU:BNL
|
-0.252x |
|
Emdeki Utama Tbk PT
JK:MDKI
|
0.013x |
|
Indah Prakasa Sentosa PT Tbk
JK:INPS
|
-0.124x |
|
United Homes Group Inc.
NASDAQ:UHG
|
0.021x |
|
Investors House
HE:INVEST
|
0.029x |
Annual Cash Flow Conversion Efficiency for RHYTHM Biosciences Ltd (2017–2025)
The table below shows the annual cash flow conversion efficiency of RHYTHM Biosciences Ltd from 2017 to 2025. For the full company profile with market capitalisation and key ratios, see market value of RHYTHM Biosciences Ltd.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | AU$659.89K ≈ $466.92K |
AU$-2.92 Million ≈ $-2.07 Million |
-4.427x | +37.45% |
| 2024-06-30 | AU$867.17K ≈ $613.58K |
AU$-6.14 Million ≈ $-4.34 Million |
-7.077x | -497.55% |
| 2023-06-30 | AU$5.87 Million ≈ $4.16 Million |
AU$-6.96 Million ≈ $-4.92 Million |
-1.184x | -40.49% |
| 2022-06-30 | AU$7.37 Million ≈ $5.22 Million |
AU$-6.21 Million ≈ $-4.40 Million |
-0.843x | +73.37% |
| 2021-06-30 | AU$1.71 Million ≈ $1.21 Million |
AU$-5.40 Million ≈ $-3.82 Million |
-3.165x | -112.71% |
| 2020-06-30 | AU$1.84 Million ≈ $1.30 Million |
AU$-2.74 Million ≈ $-1.94 Million |
-1.488x | -195.92% |
| 2019-06-30 | AU$5.85 Million ≈ $4.14 Million |
AU$-2.94 Million ≈ $-2.08 Million |
-0.503x | -152.79% |
| 2018-06-30 | AU$8.30 Million ≈ $5.87 Million |
AU$-1.65 Million ≈ $-1.17 Million |
-0.199x | -2177166.56% |
| 2017-06-30 | AU$1.42 Million ≈ $1.01 Million |
AU$-13.00 ≈ $-9.20 |
0.000x | -- |
About RHYTHM Biosciences Ltd
Rhythm Biosciences Limited, a medical diagnostics company, provides blood tests for the detection of cancers in Australia and the United States. It offers ColoSTAT, a blood test for the early detection of colorectal cancer; and geneType, a personalized predictive test for predicting risk of chronic disease development. The company was incorporated in 2017 and is headquartered in Parkville, Austra… Read more